Immune checkpoint inhibitors in bladder cancer therapy: the experience with avelumab

Immune checkpoint inhibitors have revolutionized the treatment of urothelial carcinoma. They are now part standard care for locally advanced or metastatic Maintenance therapy with avelumab has been found to be most effective compared other immune inhibitors. To date, platinum-containing chemotherapy followed by maintenance is only regimen that significantly improved overall survival in patients bladder cancer. The article presents experience on example 3 clinical cases inoperable forms treating who achieved stabilization and received was retrospectively analyzed. age ranged from 66 79 years, study included two men one woman. In cases, muscle-invasive cancer initially verified, – progression 7 years after start non-muscle-invasive Only volumetric formation radically removed, while distant metastases were detected 20 months operation, rest did not receive radical treatment. general condition allowed all a full course (gemcitabine + cisplatin gemcitabine carboplatin), partial remission achieved. immunotherapy started within month completion chemotherapy. duration currently ranges 17 months; oncological process cases. No clinically significant adverse side effects noted any Our corresponds world practice illustrates efficacy safety this drug.